{"id":45760,"date":"2025-11-04T21:31:09","date_gmt":"2025-11-04T13:31:09","guid":{"rendered":"https:\/\/flcube.com\/?p=45760"},"modified":"2025-11-04T21:31:11","modified_gmt":"2025-11-04T13:31:11","slug":"cstone-receives-nmpa-approval-for-cs2009-phase-ii-trial-in-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45760","title":{"rendered":"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors"},"content":{"rendered":"\n<p>China\u2011based CStone Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/quote\/2616:HKG\">HKG: 2616<\/a>), announced today that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its Phase\u202fII program evaluating <strong>CS2009<\/strong>\u2014a novel tri\u2011specific antibody targeting PD\u20111, VEGFA, and CTLA\u20114\u2014in patients with advanced solid tumors.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-why-cs2009-matters\">Why CS2009 Matters<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Impact<\/th><th>Clinical Context<\/th><\/tr><\/thead><tbody><tr><td><strong>Tri\u2011specific design<\/strong><\/td><td>Simultaneous blockade of three major immune checkpoints<\/td><td>Addresses resistance pathways in solid\u2011tumor microenvironments<\/td><\/tr><tr><td><strong>Synergistic pharmacology<\/strong><\/td><td>Enhanced anti\u2011tumor activity compared to single or dual antibodies<\/td><td>Pre\u2011clinical data show superior tumor regression<\/td><\/tr><tr><td><strong>Broad indication coverage<\/strong><\/td><td>15 cohorts across 9 tumor types (NSCLC, HCC, CRC, PROC, TNBC, ES\u2011SCLC, CC, GC\/GEJC, ESCC)<\/td><td>Positions CS2009 as a versatile platform in oncology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-phase-ii-clinical-trial-blueprint\">Phase\u202fII Clinical Trial Blueprint<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global, multi\u2011center, parallel\u2011expansion design<\/strong> \u2013 Allows simultaneous safety, PK\/PD, and efficacy assessment across diverse tumor types.<\/li>\n\n\n\n<li><strong>Cooperation with leading oncology networks<\/strong> \u2013 Initial enrollment underway in Australia, soon expanding to China and the U.S.<\/li>\n\n\n\n<li><strong>Monotherapy and combination cohorts<\/strong> \u2013 Patients receive CS2009 alone or with standard\u2011of\u2011care regimens, enabling rapid translational insights.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-amp-commercial-outlook\">Regulatory &amp; Commercial Outlook<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA IND clearance<\/strong> speeds entry into the Chinese market, a critical gateway for oncology drug commercialization.<\/li>\n\n\n\n<li><strong>Investor sentiment<\/strong>: The approval has already reflected positively in CStone\u2019s Hong Kong share price, with analysts noting potential upside once safety profiles are confirmed.<\/li>\n\n\n\n<li><strong>Future commercialization<\/strong> \u2013 Pending results could pave the way for accelerated approvals in the U.S. FDA and other major jurisdictions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45761,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,188,856,28],"class_list":["post-45760","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cstone-pharmaceuticals","tag-hkg-2616","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its Phase\u202fII program evaluating CS2009\u2014a novel tri\u2011specific antibody targeting PD\u20111, VEGFA, and CTLA\u20114\u2014in patients with advanced solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45760\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"China\u2011based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its Phase\u202fII program evaluating CS2009\u2014a novel tri\u2011specific antibody targeting PD\u20111, VEGFA, and CTLA\u20114\u2014in patients with advanced solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45760\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T13:31:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-04T13:31:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0407.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45760#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45760\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors\",\"datePublished\":\"2025-11-04T13:31:09+00:00\",\"dateModified\":\"2025-11-04T13:31:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45760\"},\"wordCount\":256,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45760#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0407.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CStone Pharmaceuticals\",\"HKG: 2616\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45760#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45760\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45760\",\"name\":\"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45760#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45760#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0407.webp\",\"datePublished\":\"2025-11-04T13:31:09+00:00\",\"dateModified\":\"2025-11-04T13:31:11+00:00\",\"description\":\"China\u2011based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its Phase\u202fII program evaluating CS2009\u2014a novel tri\u2011specific antibody targeting PD\u20111, VEGFA, and CTLA\u20114\u2014in patients with advanced solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45760#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45760\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45760#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0407.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0407.webp\",\"width\":1080,\"height\":608,\"caption\":\"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45760#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its Phase\u202fII program evaluating CS2009\u2014a novel tri\u2011specific antibody targeting PD\u20111, VEGFA, and CTLA\u20114\u2014in patients with advanced solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45760","og_locale":"en_US","og_type":"article","og_title":"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors","og_description":"China\u2011based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its Phase\u202fII program evaluating CS2009\u2014a novel tri\u2011specific antibody targeting PD\u20111, VEGFA, and CTLA\u20114\u2014in patients with advanced solid tumors.","og_url":"https:\/\/flcube.com\/?p=45760","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-04T13:31:09+00:00","article_modified_time":"2025-11-04T13:31:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0407.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45760#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45760"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors","datePublished":"2025-11-04T13:31:09+00:00","dateModified":"2025-11-04T13:31:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45760"},"wordCount":256,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45760#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0407.webp","keywords":["Clinical trial approval \/ initiation","CStone Pharmaceuticals","HKG: 2616","Multi-specific antibodies"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45760#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45760","url":"https:\/\/flcube.com\/?p=45760","name":"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45760#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45760#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0407.webp","datePublished":"2025-11-04T13:31:09+00:00","dateModified":"2025-11-04T13:31:11+00:00","description":"China\u2011based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its Phase\u202fII program evaluating CS2009\u2014a novel tri\u2011specific antibody targeting PD\u20111, VEGFA, and CTLA\u20114\u2014in patients with advanced solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45760#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45760"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45760#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0407.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0407.webp","width":1080,"height":608,"caption":"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45760#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CStone Receives NMPA Approval for CS2009 Phase\u202fII Trial in Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0407.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45760"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45760\/revisions"}],"predecessor-version":[{"id":45762,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45760\/revisions\/45762"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45761"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}